The role of postoperative chemotherapy in patients who undergoing surgery following chemoradiotherapy of initially unresectable rectal cancer

Michał Jankowski¹,², Manuela Las-Jankowska¹,³, Dariusz Bała¹,², Wojciech Zegarski¹,²

Introduction. Preoperative chemoradiotherapy (preCRT) improves local control of rectal cancer and such is particularly merited for treating locoregionally advanced tumors. Nevertheless, the role of postoperative chemotherapy (postCT) in such patients is currently disputed.

Materials. Subjects were 75 patients with unresectable cT3–4 and/or N+ tumors who underwent radical surgery following preCRT between January 2003 and December 2012 at the Oncology Centre in Bydgoszcz. PostCT was subsequently used in 32 (43%) of these patients.

Results. There were 20 abdominoperineal resections (APR), 50 anterior resections (AR) and 5 Hartmann’s procedures (HART) performed in the patient group, where respectively 30%, 46% and 60%, received systemic treatment. Based on postoperative histopathological assessment, disease staging was assigned as follows: stage III for 32 (43%) patients, stage II for 22 (29%) and stage I for 15 (20%). Pathologic complete pathological response (pCR) was seen in 6 cases (8%). In the postCT+ group, disease stage III was observed in 13 (41%) patients. A three-year survival was observed in 43 patients; 25 (58%) and 18 (56%) of patients respectively undergoing either postCT− or postCT+. A five-year survival was noted in 26 patients; 19 (44%) and 7 (22%) in both groups, respectively.

Conclusion. Together with the most recent reports, our study demonstrates that postoperative chemotherapy has no significant effect on the outcomes of oncological treatment in those patients having undergone preoperative chemoradiotherapy for locoregionally advanced rectal cancer.

Key words: rectal cancer, postoperative chemotherapy, preoperative chemoradiotherapy, unresectable rectal cancer

Introduction
Rectal cancer (ICD 10: c20) is the most common location of colorectal cancer, of which in 2013, there were 5898 people diagnosed with this condition in Poland [1]. Therapy is determined by the disease stage upon diagnosis and involves a number of surgical procedures, as well as radio- and chemotherapies. In locoregionally advanced tumors, the most common treatment involves a surgical resection and radiation therapy combined with systemic treatment. It is therefore crucial that preoperative diagnostics and eligibility for treatment (MRI, CT) be appropriately applied to patient diagnosis and treatment.

Methods
“Unresectable rectal cancer”
This should be diagnosed before surgery, when performing radical resection is fraught with uncertainty due to the risk of positive surgical margins. The tumor is most common-
ly immobile during rectal examination (Tab. I). Pelvic MRI scans are the most efficacious means for diagnosing rectal tumors. An "unresectable rectal cancer" without distant metastases occurs in about 10% of patients with rectal cancer.

**Preoperative treatment**

Perioperative radiotherapy reduces the local recurrence rate in patients with rectal cancer [2, 3]. When used prior to the main treatment, it also allows the desired outcome to be achieved with a lower toxicity [4]. Reduced tumor size is usually observed several weeks after radiotherapy is completed [5, 6]. Combining chemo- and radiotherapy increases treatment efficacy [7].

The treatment regimen for the study group consisted of 28 fractions of 1.8–2 Gy per fraction and a 5.4 Gy bolus.

**Postoperative chemotherapy**

This has been used since the 1970s, after studies had been published on its efficacy in dealing with colonic cancer patients; being based on fluoropyrimidine [8]. Such therapy showed that the overall survival (OS) and disease-free survival (DFS) rates could be improved by more than 10% [9].

Rectal cancer patients are qualify for this treatment because the indications are similar to those of colon cancer. The standard duration lasts about 24 weeks, with the treatment being well tolerated, with the most important of the side effects being cardiotoxicity affecting its therapeutic tolerance.

In recent years using postoperative chemotherapy in patients with rectal cancer, particularly following earlier preoperative chemoradiotherapy, is widely considered controversial and is disputed.

**Prognosis**

Prognoses for rectal cancer patients, i.e. overall survival, (OS), disease free survival (DFS), depends on how radical resection (R0) is performed with total mesorectal excision (TME) [10]. Locoregionally advanced rectal cancer (cT3–4 and/or cN0/+ stage) is associated with higher local recurrence rates following surgical curative treatment during the postoperative period. Preoperative chemoradiotherapy (preCRT) facilitates local control over rectal cancer; increasing the numbers of R0 resections and decreasing local recurrence rates. This type of treatment is especially justified for loco-regionally advanced tumors.

Despite the progress achieved in local and regional treatment, the final outcomes in rectal cancer are still governed by the ≥ 25% rate of distant metastases following radical resection.

**Material**

Subjects were 787 patients with WHO stage I–III rectal tumors that underwent radical surgery between 2003–2012 at the Department of Oncological Surgery of the Nicolaus Copernicus University Medical Centre, Centre of Oncology in Bydgoszcz. Seventy-five patients were preoperatively diagnosed (by computed tomography/magnetic resonance of the pelvis and abdomen) with cT3–4 and/or cN0/+ stage and qualified for preoperative chemoradiotherapy (28 fractions: 25/1.8 Gy, and bolus 5.4 Gy, combined with 2 cycles of 5Fu with leucovorin).

After surgery, postoperative chemotherapy (post-CT+) was administered to 32 patients while 43 did not undergo any postoperative systematic treatment (post-CT–). In the former group, 13 patients did not receive the complete treatment (8 cycles 5Fu/Leu, 40%). Table II presents the characteristics of these two study groups.

The reasons for abandoning the systemic treatment (post-CT–) are listed in Table III.

**Results**

There were no statistically significant differences found when comparing 5-year overall survival (OS) rates between both groups as estimated by the Kaplan-Meier method (Fig. 1). Nor were any such differences observed in either of the 5-year disease-free survival (DFS) rates.

### Table II. Patients’ characteristics (n = 75)

<table>
<thead>
<tr>
<th></th>
<th>post-CT+</th>
<th>post-CT–</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Above 75 years of age</td>
<td>4</td>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td>Below 75 years of age</td>
<td>28</td>
<td>37</td>
<td>65</td>
</tr>
<tr>
<td>AR</td>
<td></td>
<td></td>
<td>50</td>
</tr>
<tr>
<td>APR</td>
<td></td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>HR</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>I/II</td>
<td>19</td>
<td>24</td>
<td>33</td>
</tr>
<tr>
<td>III</td>
<td>13</td>
<td>19</td>
<td>32</td>
</tr>
</tbody>
</table>

### Table III. Causes for abandoning adjuvant chemotherapy (post-CT–)

<table>
<thead>
<tr>
<th>Cause</th>
<th>(n = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inadequate qualifications of the oncologist— age</td>
<td>5</td>
</tr>
<tr>
<td>Inadequate qualifications of the oncologist— other</td>
<td>12</td>
</tr>
<tr>
<td>Extension of postoperative period— complications</td>
<td>6</td>
</tr>
<tr>
<td>Extension of postoperative period— other</td>
<td>4</td>
</tr>
<tr>
<td>Other</td>
<td>4</td>
</tr>
<tr>
<td>Unknown</td>
<td>12</td>
</tr>
</tbody>
</table>
The overall (n = 75) rate of local recurrences was 14%, without any statistically significant difference between groups (Tab. IV). The local recurrence rate was higher in groups at the lower tumor stages by 4.2% [11].

Discussion

**The effect of postoperative chemotherapy on overall survival (OS) and disease-free survival (DFS) in patients after preoperative chemoradiotherapy**

Indications for postoperative chemotherapy in patients undergoing radical treatment of rectal cancer are largely based on the outcomes of colonic cancer treatment which show a 24–33% reduced risk of death as a result of post-CT in patients with regional metastases (pN+) [12]. In their analysis mainly based on studies prior to 2000 and without the use of the TME technique, Petersen et al. reported relative improvements in OS and DFS following post-CR, respectively amounting to 17% and 25% [13].

Nevertheless adjuvant chemotherapy in rectal cancer patients after previous preoperative therapy has been the subject of a significant dispute/controversy in recent years. In their meta-analysis based on 4 studies [14–17] and the data from 1196 patients, Breugom et al. [18] demonstrated that postoperative chemotherapy had no effect on improving overall survival (OS), nor disease-free survival (DFS) or on the rates of all recurrences.

Similar results were published by Bujko et al. in their meta-analysis based on similar study material [19].

Nonetheless adjuvant chemotherapy in rectal cancer patients after previous preoperative therapy has been the subject of a significant dispute/controversy in recent years. In their meta-analysis based on 4 studies [14–17] and the data from 1196 patients, Breugom et al. [18] demonstrated that postoperative chemotherapy had no effect on improving overall survival (OS), nor disease-free survival (DFS) or on the rates of all recurrences.

**The importance of the distance between the tumor and the anorectal line**

When tumors are located within the upper part of rectum (10–15 cm), postoperative chemotherapy beneficially affects disease free survival and the incidence of distant metastases [14]. However, one should keep in mind that for tumors located within the upper part of the rectum (more than 10 cm from the anorectal line), preoperative radiation should be administered only in exceptional cases [21].

An analysis by the Swedish Cancer Registry based on 436 patients aged above 75 years suffering regional disease (WHO stage III), confirms that postoperative chemotherapy is effective only in tumors located more than 10 cm above the anorectal line (HR 0.54; 95% CI 0.3–0.9, p < 0.05) [22]. Such results may be explained by the similarities in anatomical structure of the colon and the upper rectum.

---

**Table IV. Treatment outcomes**

<table>
<thead>
<tr>
<th></th>
<th>post-CT+</th>
<th>post-CT−</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>32</td>
<td>43</td>
<td>75</td>
</tr>
<tr>
<td>Local recurrence</td>
<td>15.6%</td>
<td>13.9%</td>
<td>14.7%</td>
</tr>
</tbody>
</table>

---

**Figure 1.** Overall survival (OS) in patients from both groups (with and without postoperative chemotherapy)
Locoregional advanced

In locoregionally advanced (cT3–4, mrf+) and/or regionally advanced (cN+), the most effective treatment involves preoperative radiotherapy, if possible combined with chemotherapy and a radical (R0) resection procedure by means of the total mesorectal excision (TME) technique [21]. Despite such management, the rates of recurring disease are significantly higher in this group [23]. Correct preoperative diagnostics, preferably by means of pelvic magnetic resonance imaging [24] is thus the crucial element of patient diagnosis that facilitates customization of treatment.

In the retrospectively analyzed group, postoperative chemotherapy was found not to improve oncological outcomes (OS, DFS) despite that the comparison was conducted between apartent group treated according to optimum principles (post-CT+) and a heterogeneous patient group in whom systemic treatment was abandoned (post-CT–). A randomized trial is thereby needed to confirm that systemic treatment has no effect overall outcomes.

Conclusions

Despite abandoning postoperative chemotherapy, OS and DFS rates were not reduced in patients undergoing radical surgical treatment following preoperative chemoradiotherapy of locoregional advanced rectal cancer.

Conflict of interest: none declared

Michał Jankowski, MD, PhD
Nicolaus Copernicus University
Collegium Medicum
Oncology Centre — Prof. Franciszek Łukaszczyk Memorial Hospital
Chair of Surgical Oncology
ul. Romanańskiej 2
85–796 Bydgoszcz, Poland
e-mail: michaljankowski@post.pl

Received: 14 Jun 2017
Accepted: 18 Sept 2017

References